Stroke Clinical Trial
Official title:
Microbleeds and Genetic Risk Factors to Predict the Risk of Intracranial Haemorrhage in Patients Treated With Anticoagulation Following Cardioembolic Stroke Due to Atrial Fibrillation
Study I: CROMIS-2 (AF) Prospective cohort study of patients anticoagulated after
cardioembolic stroke An observational inception cohort study (n=1425) of patients throughout
the United Kingdom (UK) - (79 hospitals) started on best practice oral anticoagulant (without
prior use) for presumed cardioembolic ischaemic stroke due to non-valvular AF with follow up
for the occurrence of intracerebral haemorrhage (ICH) and ischaemic stroke for an average of
two years. The main baseline exposures (risk factors of interest) are the presence of
cerebral microbleeds (CMBs) on magnetic resonance imaging (MRI), and genetic polymorphisms in
candidate genes with potential functional relevance to ICH risk.
Study II: CROMIS-2 (ICH) Observational and genetics study of intracerebral haemorrhage The
investigators will also recruit 600 patients admitted to participating centres with ICH (with
a target of at least 300 anticoagulant-related ICH cases) and collect DNA to increase the
power of the genetic studies. The investigators will collect clinical and imaging data from
these ICH cases to investigate risk factors associated with anticoagulant-related ICH
compared to non anticoagulant-related ICH.
Background Over the last decade, increasing use of oral anticoagulants to prevent
cardioembolic ischaemic stroke due to atrial fibrillation (AF) in an ageing population has
led to a five-fold increase in the incidence of anticoagulant-related intracranial
haemorrhage (ICH) - a rare but unpredictable and catastrophic complication. Cerebral
microbleeds (CMBs) on magnetic resonance imaging (MRI) may predict ICH risk, as may genetic
polymorphisms influencing brain small-vessel integrity or anticoagulation stability.
Aims To establish the value of CMBs and genetic factors in predicting symptomatic ICH
following best practice oral anticoagulation to prevent recurrent ischaemic stroke due to AF.
Methods CROMIS-2: Study I (AF) - Prospective, multicentre, inception cohort study in 1425
patients with ischaemic stroke due to AF started on best practice oral anticoagulation.
Patients will have genetic testing and standardized MRI including Gradient recalled Echo
(GRE) at baseline, with follow-up by postal questionnaire (and clinical assessment or medical
records surveillance after suspected events), and where possible there will be an in person
clinical assessment at 2 years. The investigators will compare the rate of symptomatic ICH
between CMB and CMB-free patients and test for associations with plausible candidate genes.
The investigators aim to develop and validate a risk model to predict symptomatic ICH
following best practice oral anticoagulation to prevent recurrent ischaemic stroke due to AF.
CROMIS-2: Study II (ICH) - An observational study of ICH investigating genetic, clinical and
radiological risk factors associated with anticoagulant-related ICH. The investigators will
recruit patients admitted to participating centres with ICH (with a target of at least 300
anticoagulant-related ICH cases) and collect DNA to increase the power of the genetic
studies. The investigators will collect clinical and imaging data from these ICH cases to
investigate risk factors associated with anticoagulant-related ICH compared to non
anticoagulant-related ICH.
Expected outcomes A successful predictive model for ICH risk after best practice oral
anticoagulation for AF will help to determine whether genetic or CMB screening should be used
in clinical practice and future trials. New genetic, clinical and radiological risk factors
associated with anticoagulant-related ICH will be identified.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
| Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
| Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
| Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
| Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
| Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
| Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
| Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
| Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
| Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
| Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
| Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
| Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
| Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
| Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
| Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
| Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
| Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
| Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
| Recruiting |
NCT05993221 -
Deconstructing Post Stroke Hemiparesis
|